Clinical Trial: A Phase 1 Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT07612189) titled 'A Phase 1 Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors' on May 21.

Brief Summary: This is a first in human (FIH), Phase 1 dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).

Study Start Date: April 22

Study Type: INTERVENTIONAL

Condition: Locally Advanced (Unresectable) or Metastatic Solid Tumors

Intervention: DRUG: NEOK002

Escalating doses of NEOK002

DRUG: NEOK002 RDE

Recommended NEOK002 dose(s) for Expansion

Recruitment Status: RECRUITING

Spon...